Author(s): Cohen JL, Cohen G, Solish N, Murray CA
Abstract Share this page
Abstract Idiopathic localized hyperhidrosis, called for hyperhidrosis, affects almost 3\% of the US population. The most frequent anatomic sites of involvement include the axillae, palms, soles, and face. For those affected, this condition can be extremely socially debilitating and interfere with work activities. Until recently, frequently ineffective topical regimens or problematic surgical procedures have been the treatments of choice. Since 1996, intracutaneous injections of botulinum toxin have been used as a minimally invasive treatment for this condition with numerous studies documenting safety, efficacy, and extremely high levels of patient satisfaction. Botulinum toxin type A (Botox) was approved by the US Food and Drug Administration in 2004 for the treatment of axillary hyperhidrosis.
This article was published in Facial Plast Surg Clin North Am
and referenced in Journal of Surgery